Izotropic Corporation Integrates Proprietary AI Algorithm into Breast CT Imaging System

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) has announced the integration of its proprietary AI-based machine-learning reconstruction algorithm into its flagship IzoView Breast CT Imaging System. Developed in collaboration with The Johns Hopkins University School of Medicine, the algorithm is designed to improve image quality while maintaining low radiation doses. This integration represents a significant advancement in breast cancer imaging technology, addressing critical limitations of current methods.

Unlike conventional denoising methods such as Model-Based Iterative Reconstruction (MBIR) and Deep Machine-Learning Reconstruction (DMLR), which are constrained by speed and workflow practicality, Izotropic's innovative approach targets image noise at its source. This methodology offers a potential breakthrough for clinical efficiency in breast cancer screening, potentially reducing examination times while enhancing diagnostic accuracy. The company's focus on improving breast cancer care through advanced imaging solutions positions this development as particularly important for early detection and treatment planning.

The integration of artificial intelligence into medical imaging systems represents a growing trend in healthcare technology, with Izotropic's solution specifically tailored for breast CT applications. By maintaining low radiation doses while improving image quality, the technology addresses two crucial concerns in medical imaging: patient safety and diagnostic precision. This balance is especially critical in breast cancer screening, where frequent imaging may be required for high-risk patients.

For investors and stakeholders following the company's progress, additional information is available through various channels including the corporate website at https://izocorp.com and regulatory filings accessible at https://sedarplus.ca. The development underscores Izotropic's commitment to advancing breast cancer care through technological innovation, potentially impacting how healthcare providers approach screening and diagnosis in clinical settings.